Rheumatoid Arthritis Research Today is a free monthly online journal that collates and summarizes the latest research about Rheumatoid Arthritis, including details on treatment, symptoms, causes, medication.

Volume 8 (2011), Issue 1 (January)

1. Predictors of the use of physical therapy services among patients with rheumatoid arthritis.
   Phys Ther, 91(1): 65-76. [Abstract] [Full-text]
2. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants.
   Arthritis Rheum, 63(1): 43-52. [Abstract] [Full-text]
3. Classification of rheumatoid arthritis: comparison of the 1987 American College of Rheumatology criteria and the 2010 American College of Rheumatology/European League Against Rheumatism criteria.
   Arthritis Rheum, 63(1): 37-42. [Abstract] [Full-text]
4. Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin-17A production.
   Arthritis Rheum, 63(1): 73-83. [Abstract] [Full-text]
5. The effect of genotype on methotrexate polyglutamate variability in juvenile idiopathic arthritis and association with drug response.
   Arthritis Rheum, 63(1): 276-85. [Abstract] [Full-text]
6. Immune complexes containing citrullinated fibrinogen costimulate macrophages via Toll-like receptor 4 and Fcγ receptor.
   Arthritis Rheum, 63(1): 53-62. [Abstract] [Full-text]
7. Antinuclear antibody-positive patients should be grouped as a separate category in the classification of juvenile idiopathic arthritis.
   Arthritis Rheum, 63(1): 267-75. [Abstract] [Full-text]
8. Efficacy and safety of an intraoral electrostimulation device for xerostomia relief: a multicenter, randomized trial.
   Arthritis Rheum, 63(1): 180-90. [Abstract] [Full-text]
9. V-region gene analysis of locally defined synovial B and plasma cells reveals selected B cell expansion and accumulation of plasma cell clones in rheumatoid arthritis.
   Arthritis Rheum, 63(1): 63-72. [Abstract] [Full-text]
10. Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts.
    Arthritis Rheum, 63(1): 26-36. [Abstract] [Full-text]
11. Measuring process of arthritis care: a proposed set of quality measures for the process of care in juvenile idiopathic arthritis.
    Arthritis Care Res (Hoboken), 63(1): 10-6. [Abstract] [Full-text]
12. Responsiveness of the ABILHAND questionnaire in measuring changes in rheumatoid arthritis patients.
    Arthritis Care Res (Hoboken), 63(1): 135-41. [Abstract] [Full-text]
13. Quality care in seniors with new-onset rheumatoid arthritis: a Canadian perspective.
    Arthritis Care Res (Hoboken), 63(1): 53-7. [Abstract] [Full-text]
14. American College of Rheumatology hybrid analysis of certolizumab pegol plus methotrexate in patients with active rheumatoid arthritis: data from a 52-week phase III trial.
    Arthritis Care Res (Hoboken), 63(1): 128-34. [Abstract] [Full-text]
15. Tocilizumab in refractory adult Still's disease.
    Arthritis Care Res (Hoboken), 63(1): 155-9. [Abstract] [Full-text]
16. Cost-effectiveness of biologics in polyarticular-course juvenile idiopathic arthritis patients unresponsive to disease-modifying antirheumatic drugs.
    Arthritis Care Res (Hoboken), 63(1): 111-9. [Abstract] [Full-text]
17. Do spouses know how much fatigue, pain, and physical limitation their partners with rheumatoid arthritis experience? Implications for social support.
    Arthritis Care Res (Hoboken), 63(1): 120-7. [Abstract] [Full-text]
18. Older age of rheumatoid arthritis onset is associated with higher activation status of peripheral blood CD4(+) T cells and disease activity.
    Clin Exp Immunol, 163(2): 157-64. [Abstract] [Full-text]
19. Immune complex-mediated cell activation from systemic lupus erythematosus and rheumatoid arthritis patients elaborate different requirements for IRAK1/4 kinase activity across human cell types.
    J Immunol, 186(2): 1279-88. [Abstract] [Full-text]
20. Older age of rheumatoid arthritis onset is associated with higher activation status of peripheral blood CD4(+) T cells and disease activity.
    Clin Exp Immunol, 163(2): 157-64. [Abstract] [Full-text]
21. Older age of rheumatoid arthritis onset is associated with higher activation status of peripheral blood CD4(+) T cells and disease activity.
    Clin Exp Immunol, 163(2): 157-64. [Abstract] [Full-text]
22. Genetic basis of autoantibody positive and negative rheumatoid arthritis risk in a multi-ethnic cohort derived from electronic health records.
    Am J Hum Genet, 88(1): 57-69. [Abstract] [Full-text]
23. Are lipid ratios less susceptible to change with systemic inflammation than individual lipid components in patients with rheumatoid arthritis?
    Angiology, 62(2): 167-75. [Abstract] [Full-text]
24. A genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis.
    Ann Rheum Dis, 70(2): 259-65. [Abstract] [Full-text]
25. IL-17A- versus IL-17F-induced intracellular signal transduction pathways and modulation by IL-17RA and IL-17RC RNA interference in rheumatoid synoviocytes.
    Ann Rheum Dis, 70(2): 341-8. [Abstract] [Full-text]
26. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis.
    Ann Rheum Dis, 70(2): 266-71. [Abstract] [Full-text]
27. Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study.
    Ann Rheum Dis, 70(2): 315-9. [Abstract] [Full-text]
28. Tumour necrosis factor (TNF)-blocking agents in juvenile psoriatic arthritis: are they effective?
    Ann Rheum Dis, 70(2): 337-40. [Abstract] [Full-text]
29. Anti-citrullinated protein antibodies have a low avidity compared with antibodies against recall antigens.
    Ann Rheum Dis, 70(2): 373-9. [Abstract] [Full-text]
30. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept.
    Ann Rheum Dis, 70(2): 284-8. [Abstract] [Full-text]
31. Fcγ receptor IIIb polymorphism and use of glucocorticoids at baseline are associated with infusion reactions to infliximab in patients with rheumatoid arthritis.
    Ann Rheum Dis, 70(2): 299-304. [Abstract] [Full-text]
32. Urinary type II collagen C-terminal peptide is associated with synovitis and predicts structural bone loss in very early inflammatory arthritis.
    Ann Rheum Dis, 70(2): 331-3. [Abstract] [Full-text]
33. No overall progression and occasional repair of erosions despite persistent inflammation in adalimumab-treated rheumatoid arthritis patients: results from a longitudinal comparative MRI, ultrasonography, CT and radiography study.
    Ann Rheum Dis, 70(2): 252-8. [Abstract] [Full-text]
34. A genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis.
    Ann Rheum Dis, 70(2): 259-65. [Abstract] [Full-text]
35. IL-17A- versus IL-17F-induced intracellular signal transduction pathways and modulation by IL-17RA and IL-17RC RNA interference in rheumatoid synoviocytes.
    Ann Rheum Dis, 70(2): 341-8. [Abstract] [Full-text]
36. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis.
    Ann Rheum Dis, 70(2): 266-71. [Abstract] [Full-text]
37. Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study.
    Ann Rheum Dis, 70(2): 315-9. [Abstract] [Full-text]
38. Tumour necrosis factor (TNF)-blocking agents in juvenile psoriatic arthritis: are they effective?
    Ann Rheum Dis, 70(2): 337-40. [Abstract] [Full-text]
39. Anti-citrullinated protein antibodies have a low avidity compared with antibodies against recall antigens.
    Ann Rheum Dis, 70(2): 373-9. [Abstract] [Full-text]
40. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept.
    Ann Rheum Dis, 70(2): 284-8. [Abstract] [Full-text]
41. Fcγ receptor IIIb polymorphism and use of glucocorticoids at baseline are associated with infusion reactions to infliximab in patients with rheumatoid arthritis.
    Ann Rheum Dis, 70(2): 299-304. [Abstract] [Full-text]
42. Urinary type II collagen C-terminal peptide is associated with synovitis and predicts structural bone loss in very early inflammatory arthritis.
    Ann Rheum Dis, 70(2): 331-3. [Abstract] [Full-text]
43. No overall progression and occasional repair of erosions despite persistent inflammation in adalimumab-treated rheumatoid arthritis patients: results from a longitudinal comparative MRI, ultrasonography, CT and radiography study.
    Ann Rheum Dis, 70(2): 252-8. [Abstract] [Full-text]
44. Endoscopic treatment of salivary glands affected by autoimmune diseases.
    J Oral Maxillofac Surg, 69(2): 476-81. [Abstract] [Full-text]
45. Agreement between proxy and adolescent assessment of disability, pain, and well-being in juvenile idiopathic arthritis.
    J Pediatr, 158(2): 307-12. [Abstract] [Full-text]
46. Relapse rate of uveitis post-methotrexate treatment in juvenile idiopathic arthritis.
    Am J Ophthalmol, 151(2): 217-22. [Abstract] [Full-text]
47. Cardiac autonomic function in patients with rheumatoid arthritis: heart rate turbulence analysis.
    Anadolu Kardiyol Derg, 11(1): 11-5. [Abstract] [Full-text]
48. Translational pharmacokinetics and pharmacodynamics of an FcRn-variant anti-CD4 monoclonal antibody from preclinical model to phase I study.
    Clin Pharmacol Ther, 89(2): 283-90. [Abstract] [Full-text]
49. Relapse rate of uveitis post-methotrexate treatment in juvenile idiopathic arthritis.
    Am J Ophthalmol, 151(2): 217-22. [Abstract] [Full-text]
50. Cardiac autonomic function in patients with rheumatoid arthritis: heart rate turbulence analysis.
    Anadolu Kardiyol Derg, 11(1): 11-5. [Abstract] [Full-text]
51. A bifunctional role for group IIA secreted phospholipase A2 in human rheumatoid fibroblast-like synoviocyte arachidonic acid metabolism.
    J Biol Chem, 286(4): 2492-503. [Abstract] [Full-text]
52. Azathioprine as a treatment option for uveitis in patients with juvenile idiopathic arthritis.
    Br J Ophthalmol, 95(2): 209-13. [Abstract] [Full-text]
53. Global DNA methylation, DNMT1, and MBD2 in patients with rheumatoid arthritis.
    Immunol Lett, 135(1): 96-9. [Abstract] [Full-text]
54. Grape seed proanthocyanidin extract (GSPE) differentially regulates Foxp3(+) regulatory and IL-17(+) pathogenic T cell in autoimmune arthritis.
    Immunol Lett, 135(1): 50-8. [Abstract] [Full-text]
55. Modeling Sjögren's syndrome with Id3 conditional knockout mice.
    Immunol Lett, 135(1): 34-42. [Abstract] [Full-text]
56. Global DNA methylation, DNMT1, and MBD2 in patients with rheumatoid arthritis.
    Immunol Lett, 135(1): 96-9. [Abstract] [Full-text]
57. Grape seed proanthocyanidin extract (GSPE) differentially regulates Foxp3(+) regulatory and IL-17(+) pathogenic T cell in autoimmune arthritis.
    Immunol Lett, 135(1): 50-8. [Abstract] [Full-text]
58. Modeling Sjögren's syndrome with Id3 conditional knockout mice.
    Immunol Lett, 135(1): 34-42. [Abstract] [Full-text]
59. DEK in the synovium of patients with juvenile idiopathic arthritis: characterization of DEK antibodies and posttranslational modification of the DEK autoantigen.
    Arthritis Rheum, 63(2): 556-67. [Abstract] [Full-text]
60. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series.
    Arthritis Rheum, 63(2): 545-55. [Abstract] [Full-text]
61. MicroRNA expression profiles as biomarkers of minor salivary gland inflammation and dysfunction in Sjögren's syndrome.
    Arthritis Rheum, 63(2): 535-44. [Abstract] [Full-text]
62. Altered expression of microRNA-203 in rheumatoid arthritis synovial fibroblasts and its role in fibroblast activation.
    Arthritis Rheum, 63(2): 373-81. [Abstract] [Full-text]
63. Body mass index and clinical response to infliximab in rheumatoid arthritis.
    Arthritis Rheum, 63(2): 359-64. [Abstract] [Full-text]
64. The risk of cancer in patients with rheumatoid arthritis: a nationwide cohort study in Taiwan.
    Arthritis Rheum, 63(2): 352-8. [Abstract] [Full-text]
65. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents.
    Arthritis Rheum, 63(2): 337-45. [Abstract] [Full-text]
66. The incidence of gastrointestinal perforations among rheumatoid arthritis patients.
    Arthritis Rheum, 63(2): 346-51. [Abstract] [Full-text]

© 2004-2012 Rheumatoid Arthritis Research Today. All Rights Reserved.